Hospira’s Global Quality Compliance Strategy Questioned In FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Letter citing GMP violations at an Italian manufacturing site is another black mark for the sterile generic injectables maker, which is seeking to become among the handful of early biosimilar entrants in the U.S. market.